Semaglutide 2.4 mg produces weight-independent liver benefits among individuals with metabolic dysfunction-associated steatohepatitis.
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY ...
AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis ...
The ABC can reveal that in July last year, Queensland Health department became aware of "inconsistencies" in records of the ...
A Phase 2 trial testing experimental therapy CAL101 in people with IPF is recruiting participants. CAL101 has been granted ...
Altimmune continues developing pemvidutide for MASH but has yet to secure a partner or acquisition despite sector M&A ...
Introduction Chronic kidney disease (CKD) affects 1 in 10 people worldwide and can progress towards kidney failure, which is ...
The Scleroderma Treatment Market is on track to experience transformative growth, rising from USD 1.8 billion in 2025 to USD 3.0 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.5 ...
CHICAGO -- People who died with systemic lupus erythematosus (SLE) were far more likely than car crash victims to have severe ...
Study reveals chronic kidney disease of unknown origin is a rising health threat in Telangana, affecting younger, healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback